Press releases

WINNIPEG, Manitoba (February 2, 2005) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms, is pleased announce the appointment of two new executives to its management team.

Mr. Gord Froehlich joins Kane Biotech as Vice-President, Business Development, and will be responsible for implementing the Company's strategic objectives, developing and managing business relationships with potential partners and collaborators, and directing the licensing and marketing of Kane Biotech's portfolio of products.

Mr. Froehlich has broad business development experience. Previously he was both a Vice President and Director with Monsanto Canada where he expanded his understanding of the licensing, acquisition and commercialization of biotechnology products both domestically and internationally. Mr. Froehlich has also practiced strategic thinking through service on the Board of Directors of several companies and as Governor and Director with the Winnipeg Commodity Exchange.

"We are building an experienced and product-focused team at Kane Biotech", stated Mr. Marcus Enns, President of Kane Biotech. "As we continue towards product commercialization, we are excited about Mr. Froehlich's proven ability to bring biotech products to market."

Kane Biotech also welcomes Ms. April Manness, CGA, to its executive group as Chief Financial Officer. Ms. Manness has held senior financial management and accounting positions with several private and public biotech companies, including Medicure Inc. and Miraculins Inc.

"Both Gord and April will play instrumental roles in helping us achieve our goal of being a leading developer of products that combat bacterial biofilms", added Mr. Enns. "We look forward to benefiting from their experience and expertise."

About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. The Company is developing products for the prevention and dispersal of biofilms focused on the genetic mechanisms of biofilm formation, and originally based upon the discovery of over 60 novel anti-biofilm targets.

Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay. Biofilms are estimated to be responsible for 65% of all human infections. Biofilms cost industry, cities and hospitals in excess of $500 billion each year. Researchers have only recently begun to appreciate the significance of biofilms and the ramifications of their existence.

For more information, please contact:

Marcus Enns
President
Kane Biotech Inc.
204-487-2328 phone
204-488-9823 fax
info@kanebiotech.com
www.kanebiotech.com

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. This release is not to be construed as an offer to sell, or a solicitation for an offer to buy or trade securities